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ÖZET
Amaç: Bu çalışma hipertiroidizmli hastalarda tiroid hor-
monlarının  lipid  profilini,  eritrosit  sedimentasyon  hızını 
(ESR), serum total homosistein (t-hcy), leptin, fibrinojen 
ve C-reaktif protein (CRP) düzeylerini etkileyip etkileme-
diğini tespit etmek için tasarlanmıştır.
Gereç ve yöntem: Bu çalışma yaş ortalaması 41.8±2.4 
yıl  arasında  olan  23  hipertiroid  (3  erkek/  20  kadın)  ile 
gerçekleştirildi. Homosistein, leptin, fibrinojen, CRP, to-
tal kolesterol (TK), yüksek dansiteli lipoprotein kolesterol 
(HDL-K), düşük dansiteli lipoprotein kolestrol (LDL-K)’ün 
serum düzeyleri ve ESR ölçüldü ve vücut kütle indeksi 
(BMI) tedaviden önce ve sonra hesaplandı.
Bulgular: Hipertiroid hastalarının tedavi öncesi t-hcy, TC, 
LDL-Kolesterol, HDL-Kolesterol düzeyleri ve BMI tedavi 
sonrası düzeylerden daha düşüktü (tüm değişkenler için, 
p<0.001). Bununla birlikte, fibrinojen ve ESR tedaviden 
sonra azaldı (sırasıyla, p<0.001; p<0.05). Tedavi öncesi 
ve sonrası leptin ve CRP seviyeleri arasında fark yoktu 
(p>0.05). Tedavi öncesi ve sonrası TC ve LDL-K serbest 
triiodotironin (fT3) düzeyleri ile negatif olarak korele idi 
(sırasıyla, r=-0.588, p<0.01; r=-0.534, p<0.01; r=-0.543, 
p<0.01 ve r=-0.653, p<0.01). Tedavi öncesi HDL-K TSH 
ile tersine uyumluydu (r=-0.423, p<0.05). Tedavi öncesi 
ve sonrası LDL-K serbest tiroksin (fT4) düzeyleri ile nega-
tif uyumluydu (sırasıyla, r=-0.536, p<0.001 ve r=-0.422, 
p<0.05). Tedavi öncesi TC seviyeleri ile fT4 arasında ter-
sine bir uyum vardı (r=-0.590, p<0.01).
Sonuç: Hipertiroid durumu, yüksek plazma fibrinojen ve 
ESR düzeyleri ile ilişkilidir. Yükselmiş plazma fibrinojen ve 
ESR düzeyleri bu durumdan etkilenmiş kişiler arasında 
yüksek kardiovasküler morbidite için açıklanabilen muh-
temel bir durum olabilir. Bu değişimler düşük seviye infla-
masyonu ya da hipertitoidizmdeki dağılımı yansıtabilir.
Anahtar kelimeler: Hipertiroidi, homosistein, leptin, lipid 
profii, tedavi
ABSTRACT
Objectives: The present study was carried out to deter-
mine  whether  thyroid  hormones  affect  lipid  profile  and 
levels  of  erithrocyte  sedimentation  rate  (ESR),  serum 
total homocysteine (t-hcy), leptin, fibrinogen, C-reactive 
protein (CRP in patients with hyperthyroidism.
Materials and methods: This study was carried out on 
23 hyperthroid subjects (3 men / 20 women, mean age 
41.8 ± 2.4 years). Serum levels of homocysteine, leptin, 
fibrinogen, CRP, total cholesterol (TC), high-density lipo-
protein cholesterol (HDL-C), low-density lipoprotein cho-
lesterol (LDL-C) and ESR were measured and body mass 
index (BMI) were calculated before and after treatment of 
hyperthyroidism.
Results: Pretreatment t-hcy, TC, LDL-C, HDL-C levels 
and BMI of patients were significantly lower than those 
of the post-treatment (p<0.001, for each variable). How-
ever, fibrinogen and ESR decreased after the treatment 
(p<0.001 and p<0.05, respectively). There were no dif-
ferences in leptin and CRP levels between pre- and post-
treatment periods. Pre and post treatment TC and LDL-C 
levels were negatively correlated with free triiodothyronine 
(fT3) levels (r=-0.588, p<0.01; r=-0.534, p<0.01; r=-0.543, 
p<0.01  and  r  =-0.653,  p<0.01,  respectively).  Pre-treat-
ment HDL-C was inversely correlated with TSH (r=-0.423, 
p<0.05). Pre-post- treatment LDL-C was negatively cor-
related with free thyroxine (fT4) levels (r=-0.536, p<0.001 
and  r=-  0.422,  p<0.05  respectively).  Pre-treatment  TC 
was inversely correlated with fT4 (r=-0.590, p<0.01).
Conclusion:  Hyperthyroidism  is  associated  with  high 
plasma fibrinogen and ESR levels. Elevated plasma fi-
brinogen and ESR levels may be a possible explanation 
for  the  high  cardiovascular  morbidity  among  hyperthy-
roidic  subjects.  These  changes  may  reflect  low-grade 
inflammation or disturbances in coagulation in hyperthy-
roidism.
Keywords: Hyperthyroidism, homocysteine, leptin, lipid 
profile, treatment 
       -               -               -               -               -       E. Sütken et al. 2
Dicle Tıp Derg / Dicle Med J Cilt / Vol 37, No 1, 1-7
INTRODUCTION
Hyperthyroidism  has  profound  effects  on  cardio-
vascular system, including reduced systemic vascu-
lar resistance due to relaxation of vascular smooth 
muscle cells, enhanced heart rate and cardiac out-
put due to increase in cardiac diastolic relaxation, 
contractility  and  heart  rate1.  Hyperthyroidism  is 
characterised by reduced serum TSH levels despite 
increased free thyroxine (fT4) and free triiodothyro-
nine (fT3) levels.
Altered lipid profile is a well-known manifes-
tation of thyroid dysfunction. Both plasma LDL-C 
and  HDL-C  increase  in  hypothyroidism  and  de-
crease in hyperthyroidism2. Recently serum homo-
cysteine, C-reactive protein (CRP), fibrinogen, lep-
tin have emerged as new cardiovascular risk factors, 
but studies on changes of these markers with respect 
to thyroid function status have produced variable 
results3,4,5,6.
Thyroid  hormones  exert  effects  on  different 
levels of the hemostatic system, such as modulation 
of  fibrinolytic  activity  and  coagulation  proteins7. 
In this context, particularly alteration of fibrinogen 
levels may play a key role. High fibrinogen is an 
independent risk factor for atherosclerotic and car-
diovascular  diseases8.  Genetic  determination  and 
numerous environmental factors influence plasma 
fibrinogen levels, including inflammatory diseases, 
gender and cigarette smoking9,10. Although, several 
reports demonstrated an association between thyroid 
function and plasma fibrinogen levels the direction 
of this relation is still debatable. High plasma fibrin-
ogen levels were demonstrated in hyperthyroid as 
well as in hypothyroid states4,10.
CRP is composed of 187 amino acids and is an 
acute phase protein synthesized by the stimulation 
of  leukocyte  endogenous  mediator11.  Researchers 
have recently focused on the role of inflammatory 
reactions as a pathogenetic mechanism for athero-
sclerosis. Some studies have reported that CRP is 
increased in patients with atherosclerosis and this 
is related to prognosis. Furthermore, CRP is related 
to the development of cardiovascular disease and 
is an important factor for prognosis along with fi-
brinogen12. Anderson et al13 reported that the level 
of serum CRP is increased by more than two fold 
in patients with coronary artery disease. Despite the 
fact, no clear mechanism has been established in re-
lationship between CRP and atherosclerosis14.
Homocysteine  is  a  sulphur-containing  amino 
acid which in humans can only be derived from 
the metabolism of essential amino acid methion-
ine. Vitamin B12 is an essential cofactor for me-
thionine  synthase.  Homocysteine  is  metabolized 
by  one  of  the  two  pathways;  remethylation  and 
trans-sulphuration2,15.  Hyperhomocysteinemia  is 
an independent risk factor for atherosclerosis and 
atherothrombosis16,17. Plasma homocysteine levels 
increase in states of congenital deficiency of en-
zymes involved in homocysteine metabolic path-
way or due to deficiency of substances required for 
the metabolism of homocysteine such as folic acid, 
vitamin B12 or vitamin B6. Hyperhomocysteinemia 
has many detrimental effects in the body: Some of 
these are its free radical behaviour that leads to en-
dothelial damage and thereafter platelet activation, 
modification  of  coagulation  factors,  procoagulant 
effects  such  as  thrombosis,  oxidative  damage  in 
biological  membranes  and  proatherogenic  effects 
through LDL oxidation18,19.
Leptin, the protein product of the ob gene, is 
an important circulating signal for the regulation 
of body weight20. Furthermore, it has been found to 
increase energy expenditure in rodents21. Although 
its plasma levels have some relationship with other 
hormones such as glucocorticoids and insulin22,23 its 
precise role in the endocrine system remains to be 
determined. Abnormal thyroid function is associat-
ed with changes in body weight and energy expen-
diture, but it remains to be established whether thy-
roid hormones independently affect plasma leptin 
in humans. Several studies with diverse methodolo-
gies have addressed the field of leptin and thyroid 
function in humans24.
Hypothyroid patients gain weight despite a de-
crease  in  appetite,  whereas  hyperthyroid  patients 
lose weight despite an increase in appetite, consis-
tent with the fact that thyroid hormones play a role 
in energy expenditure. However, it remains contro-
versial whether leptin and the pituitary axis interact 
with, or whether dysregulation of leptin contributes 
to energy imbalance in thyroid states. The existing 
data on the relationship between the thyroid hor-
mones and leptin are conflicting25.
The aim of this study was to investigate lipid 
profiles,  homocystein,  fibrinogen,  C-reactive  pro-
tein, leptin concentrations in hyperthyroid patients 
before and after treatment.  
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MATERIALS AND METHODS
This  study  was  carried  out  on  23  hyperthyroid 
subjects (3 men / 20 women) (mean age 41.8±2.6 
years) who attended the Internal Medicine Clinic of 
our hospital between 2004-2005. The study proto-
col was approved by the Local Ethical Committee 
and all subjects gave informed consent.
The diagnosis of hyperthyroidism was made on 
the basis of clinical examination, elevated circulat-
ing levels of free T4 (fT4) or free T3 (fT3) and sup-
pressed TSH levels The cause of hyperthyroidism 
were Graves disease in all of the patients.
Fasting blood samples to determine the thyroid 
function TSH, fT4, fT3, leptin, t-hcy, fibrinogen, 
CRP, TC, LDL-C and HDL-C were drawn at begin-
ning of the study. Following baseline blood sam-
pling, subjects with hyperthyroidism were treated 
with  anti-thyroid  drugs  (propylthiouracil).  Serum 
creatinine levels were measured and only the pa-
tients with creatinine levels below 1.5 mg/dl were 
included in the study. Also vitamin B12 and folate 
deficiency were excluded from the study. None of 
the patients had any systemic disease other than hy-
perthyroidism and they were not taking any medica-
tion that could affect levels of inflammation mark-
ers, homocysteine, leptin or lipid levels. Final blood 
samples were drawn when the patients eventually 
became euthyroid. All patients reached euthyroid 
state after approximately 4 months.
Levels of total cholesterol, LDL-C and HDL-C 
were measured by means of B.M. Hitachi 742 autoan-
alyzer, using Boehringer Mannheim diagnostic kits 
and enzymatic methods. Levels of serum TSH, fT3 
and fT4 were measured by electrochemiluminescent 
method ( Roche-Modular analytic E-170). Plasma t-
hcy levels were determined by ELISA (Ceres 900 
HDI, Bio-tec. Instrument Inc) with Axis-Shiels AS 
original kits. Serum leptin levels were determined 
by ELISA (R&Systems, Inc.614 McKinley Place 
N.E Minneapolis. MN554 13 USA) method. CRP 
levels were measured nephelometrically (Beckman 
Image). Fibrinogen levels were measured coagulo-
metrically with Stago-Compact analyzer.
The body mass index (BMI) [wt (kg) / ht (m2)] 
was calculated using by measured height and weight 
before and after the therapy.
Statistical Analysis
The  data  are  presented  as  means  ±  standard 
error (S.E). The results were analyzed with regard 
to  statistical  significance  using  Paired  t-test  and 
Pearson correlation analysis was used to determine 
the correlation between the levels of serum thyroid 
hormones, serum lipid profiles, leptin, t-hcy, ESR 
and BMI. The level of significance was accepted as 
p<0.05.
RESULTS
Pre-treatment  and  post-treatment  TSH,  fT3,  fT4, 
t-hcy,  leptin,  fibrinogen,  CRP,  TC,  LDL-C  and 
HDL-C, BMI and ESR values in 23 hyperthyroid 
subjects are shown in Table 1. Post-treatment TSH, 
t-hcy, TC, LDL-C, HDL-C levels and BMI were 
higher than pre-treatment levels (p<0.001, for each 
pair  comparisons).  However  fT3,  fT4,  fibrino-
gen levels and ESR decreased after the treatment 
(p<0.001,  p<0.001,  p<0.001  and  p<0.05,  respec-
tively). No significant differences were found in the 
levels of CRP and leptin (p>0.05).
Table 1. BMI, fibrinogen, serum T.C, LDL-Choles-
terol,  HDL-Cholesterol,  T-Hcy,  Leptin,  fibrinogen, 
CRP levels and thyroid hormones of subjects before 
and after therapy.
Laboratory
Characteristics
Pre-therapy
(n= 23)
Post-therapy
(n= 23)
P
BMI (kg/m2) 25.1±1.0 27.6±1.1 0.001
TSH (mUL/ml) 0.032±0.016 1.58±0.29 <0.001
fT3 (pg/ml) 12.9±2.1 3.2±0.2 <0.001
fT4 (ng/dl) 3.4±0.4 1.0±0.1 <0.001
T-Hcy (µmol/l) 10.4±0.3 14.50±0.3 <0.001
Leptin (ng/ml) 68.6±23.2 70.1±2.8 n.s
Fibrinogen (mg/dl) 389.4±17.8 311.3±18.0 <0.001
CRP (mg/dl) 0.34±0.53 0.33±0.69 n.s
TC (mg/dl) 161.4±7.3 203.31±10.3 <0.001
LDL-C (mg/dl) 90.8±7.2 119.3±9.0 <0.001
HDL-C (mg/dl) 50.2±2.9 59.4±3.3 0.031
ESR (ml/h) 22.8±4.2 15.2±3.6 0.025
BMI: Body mass index, TSH: Thyroid-stimulating hor-
mone, fT3: free triiodothyronine, fT4: free thyroxine, 
T-Hcy: Total homocysteine, CRP: C- reactive protein, 
TC: Total Cholestero, LDL-C: Low density lipoprotein 
cholesterol, HDL-C: High density lipoprotein choles-
terol,  ESR:  Erythrocyte  sedimentation  rate,  n.s.  not 
significant  
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Pre-treatment, serum fT3 levels were negative-
ly correlated with TC (r=-0.588, p<0.01), LDL-C 
(r=- 0.534, p<0.01). We observed negative correla-
tion between pre-treatment serum TSH and HDL-C 
levels  (r=-  0.423,  p<0.05).  Pre-treatment  serum 
fT4  levels  were  negatively  correlated  with T.C  ( 
r=- 0.590, p<0.01) and also, post-treatment, serum 
fT4 levels were negatively correlated with LDL-C 
(r=- 0.422, p<0.05). Post-treatment, serum fT3 lev-
els were negatively correlated with TC (r=- 0.543, 
p<0.01), LDL-C (r=- 0.653, p<0.01). TSH, fT3 and 
fT4 did not correlate with BMI, fibrinogen, Leptin, 
t-hcy or ESR. (Table 2).
Table 2. The correlation coefficiants between mean BMI, T-Hcy, Leptin, fibrinogen, CRP, ESR, lipid profiles 
according to thyroid function status before and after therapy.
Before Therapy (n= 23) After Therapy (n= 23)
Laboratory
values
TSH
(mUL/ml)
fT3
(pg/ml)
fT4
(ng/dl)
TSH
(mUL/ml)
fT3
(pg/ml)
fT4
(ng/dl)
BMI (kg/m2) 0.206 -0.272 -0.301 0.132 -0.376 -0.330
T-Hcy (µmol/l) 0.090 0.182 -0.009 -0.091 0.221 0.260
Leptin(ng/ml) -0.270 0.200 -0.148 0.221 0.007 -0.128
Fibrinogen(mg/dl) -0.018 -0.210 -0.263 -0.155 -0.205 -0.016
CRP (mg/dl) -0.124 -0.124 -0.227 -0.072 -0.082 -0.087
TC (mg/dl) 0.042 -0.588* -0.590** 0.298 -0.543* -0.353
LDL-C (mg/dl) -0.108* -0.534* -0.536** 0.306* -0.653* -0.422*
HDL-C (mg/dl) -0.423** -0.080 0.014 -0.004* 0.243 0.048
ESR (ml/h) -0.115 -0.148 -0.100 0.124 -0.225 -0.186
Numbers represent r values (correlation coefficient) between the parameters, *p<0.05, ** p< 0.01
BMI: Body mass index, TSH: Thyroid-stimulating hormone, fT3: free triiodothyronine, fT4: free thyroxine, 
T-Hcy: Total homocysteine, CRP: C- reactive protein, TC: Total Cholestero, LDL-C: Low density lipoprotein 
cholesterol, HDL-C: High density lipoprotein cholesterol, ESR: Erythrocyte sedimentation rate.
DISCUSSION
There are consistent reports demonstrating that thy-
roid status is an important determinant of the plas-
ma/serum concentration of homocysteine5,26, which 
has been established as an independent risk factor of 
vascular occlusive disease27. In recent years, several 
studies have been performed in order to investigate 
plasma homocysteine levels in hypo- and hyperthy-
roid patients. While in some studies plasma homo-
cysteine levels were reported to be increased in hy-
pothyroidism, there are also studies that report plas-
ma homocysteine levels to be unchanged in hypo 
or  hyperthyroidism5,28.  Nedrebo  et  al.26  reported 
that plasma homocysteine levels were not signifi-
cantly different between hyperthyroid patients and 
euthyroid controls. Dickman et al.5 reported hyper-
homocysteinemia  in  hypothyroid  and  hypohomo-
cysteinemia in hyperthyroid patient and explained 
these  findings  by  decreased  folate  and  creatinine 
clearance  levels  in  hypothyroid  patients  and  in-
creased creatinine clearence levels in hyperthyroid 
patients.  Demirbas  et  al.28  have  found  decreased 
homocysteine levels in hyperthyroid patients after 
achievement of euthyrodism and explained this fact 
by the increased creatinine clearance levels. In our 
study, serum homocysteine levels were found to be 
increased  after  the  treatment  of  hyperthyroid  pa-
tients.
CRP is an important risk factor for atheroscle-
rosis and coronary artery disease29. Vincenzo et al30. 
proposed that CRP directly stimulates the inflamma-
tory reaction of arteriosclerosis by inducing the ex-
pression of adhesion molecule in vascular endothe-
lial cells and further hypothesized that CRP could 
be a treatment target for arteriosclerosis. Despite 
the expected differences in serum CRP levels ac-
cording to the level of thyroid dysfunction, in view   
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of the close relationship between hypothyroidism 
and atherosclerosis, studies on this topic are scarce. 
CRP levels have not been routinely used to diagnose 
thyroid disease, although many thyroid conditions 
involve inflammation. For this reason we measured 
CRP levels in hyperthyroid patients. There was no 
difference in CRP levels before and after treatment. 
Our results are in agreement with those Burggoaf31 
and Won-Young3.
Several  papers  concerning  abnormalities  of 
blood coagulation and fibrinolysis during hyperthy-
roidism have been published. Increased fibrinogen 
levels have been reported. However, there is contro-
versy concerning the presence of a hypercoagulable 
state in hyperthyroidisim32.
Various  mechanisms  regarding  the  interac-
tion  of  thyroid  hormones  and  blood  coagulation 
may explain our findings. First, enhanced fibrigo-
nen synthesis by activation of liver function may 
have contributed to the elevated plasma fibrinogen 
levels31,33,34. Secondly, a direct effect of thyroid hor-
mones on plasma protein regulation was assumed33. 
Recent in vitro studies and in vivo rat models dem-
onstrated important role of T3 in the direct up-reg-
ulation of coagulation proteins such as fibrinogen35. 
Finally, elevated plasma fibrinogen levels might be 
due to a chronic inflammatory state induced by in-
flammatory diseases of the thyroid disorders as well 
as an increase in inflammatory plasma proteins.
Our results suggest that high plasma fibrinogen 
levels might be a supplementary factor, contributing 
to the increased cardiovascular mortality in subjects 
with decreased serum TSH levels36 taking into ac-
count that fibrinogen is a major risk factor for car-
diovascular morbidity and mortality8,9. In our study, 
propylthiourasil treatment lowered fibrinogen lev-
els.
It is well-known that thyroid dysfunctions have 
profound effects on lipoprotein metabolism37,38. The 
main cause of the differences in total cholesterol 
concentrations is the alterations of LDL-C levels. 
In hyperthyroidism, the increase in LDL receptor 
mRNA leads to an increase in activity and number 
of LDL receptors37,39. This in turn, leads to a de-
crease in concentrations of LDL-C and TC levels. 
In hyperthyroid cases a decrease in HDL-C levels 
are also observed40. This decrease suggested to be 
due to increased hepatic triglyceride lipase activity. 
Through the effects of thyroid hormones, hepatic li-
pase, a decrease, in HDL2/ HDL3 is reported. The 
most prominent alteration in HDL-C is due to the 
changes in HDL2 subfraction38. In our study, we 
found increased levels TC, LDL-C and HDL-C af-
ter the treatment compared to pretreatment levels. 
These findings are consistent with the literature41.
Many studies on serum leptin levels during thy-
roid dysfunction revealed conflicting results. Some 
studies related to hyperthyroid state before and after 
treatment have shown similar leptin levels to those 
of controls20,42. However other studies showed that 
the serum leptin concentration increased during anti-
thyroid drug therapy43,44. Some authors found rela-
tive hypoleptinemia in hyperthyroid patients6,43,45. It 
has been suggested that this hypoleptinemia might 
be related to the degree of adiposity than to the lev-
els of thyroid hormones6. We have observed leptin 
levels increased with therapy but not to a statisti-
cally significant level25,46. In conclusion, adiposity 
was the major determinant of leptin concentration, 
but thyroid hormones did not appear to play any rel-
evant role in leptin synthesis and secretion in hu-
man.
In conclusion, thyroid hyperfunction is asso-
ciated with increased plasma fibrinogen and ESR 
levels which both reflects increased inflammatory 
activity. However, CRP level which also is a marker 
of inflammatory is not significantly elevated in un-
treated hyperthroid patients. Indeed, CRP levels are 
higher in untreated hyperthyroid patients compared 
to the post-treatment period. But this significance 
is  not  statistically  significant.  Since  a  low-grade 
inflammation  is  expected  in  hyperthyroid  state  it 
could be better if we studied high sensitive CRP lev-
els. Hyperthyroid state is an independent risk factor 
for elevated plasma fibrinogen levels and this may 
be a possible explanation fort he high cardiovascu-
lar morbidity among affected subjects. Fibrinogen 
levels and ESR levels significantly decrease when 
euthyroid state is achieved. The suggests that thy-
roid hyperfunction predisposes to a hypercoagula-
ble medium and also by inducing inflammation may 
contribute to the process of atherosclerotic vascular 
disease.
It is important to achieve an euthyroid state as 
soon as possible in hyperthyroid patients. However, 
normalization  of  hyperthyroid  hormones  are  fre-
quently associated with the elevation of proathero-
genic lipids. Moreover, during this period homo-  
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cysteine levels may also increase and the patient 
may gain some weight. Patients should be advised 
about caloric restriction and exercise while on treat-
ment. Also, we suggest folic acid and vitamin B12 
supplementation in order to prevent the elevation of 
serum homocysteine levels after treatment with an-
tithyroid drugs.
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